SLC5A2 and Parkinson disease: Recent studies have also demonstrated the involvement of SGLT2 inhibitor in restoring mitochondrial function and activating the autophagy-lysosomal pathways [149], deficits in both these pathways have been suggested to be pivotal in the development of neurodegenerative diseases such as PD.